Non-invasive diagnostic agents of cancer and methods of diagnosing cancer, especially leukemia and lymphoma

Abstract

The present invention is directed to novel non-invasive diagnostic tools to image cancers, especially, leukemia and non-Hodgkin's lymphomas (NHL) with minimal toxicity in vivo. The present invention represents a clear advance in the art which presently relies on tissue biopsy for diagnoses of these cancers. The novel imaging probe is capable of detecting precancerous cells, as well as their metastatic spread in tissues. This represents a quantum step forward in the diagnosis and staging of NHL using non-invasively molecular imaging techniques. This novel probe will also be useful to monitor patients response to chemotherapy treatments and other interventions or therapies used in the treatment of NHL. Compounds according to the present invention may be used as diagnostic tools for a number of conditions and diseases states as well as therapeutic agents for treating such conditions and disease states.

1 - 30 . (canceled) 
     
     
         31 . A method of diagnosing the existence and/or extent of a disease state or condition in tissue of a patient in which levels of LFA-1 or ICAM receptors are suspected of being or known to be elevated comprising administering to said patient an effective amount of at least one compound according to the following chemical structure: 
       
         
           
           
               
               
           
         
         Where Y is a —(CH 2 ) n Z— group where n is 4, Z is a NR group and R is H, and which group links the nitrogen of said NR group to a 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) group as X and wherein said DOTA group incorporates or complexes with at least one radioisotope selected from the group consisting of  90 Y,  111 In,  177 Lu,  225 Ac,  209 Bi,  213 Bi,  67 Ga,  68 Ga,  64 Cu,  67 Cu,  71 As,  72 As,  77 As,  65 Zn,  76 Br,  48 V,  49 V,  203 Pb,  209 Pb,  212 Pb,  166 Ho,  153 Pm, or a pharmaceutically acceptable salt thereof, measuring the amount of said compound which binds to said tissue in said patient, and comparing said measurement from said measuring step with a standard, wherein an elevated measurement in comparison to said standard is indicative of the existence and/or extent of said disease state or condition in said patient and said disease state or condition is an inflammatory disease, ischemia-reperfusion injury, reperfusion injury of tissue due to cardiopulmonary bypass, myocardial infarction, acute glomerulonephritis, vasculitis, reactive arthritis, dermatosis, stroke, thermal injury, hemodialysis, ulcerative colitis, necrotizing enterocolitis, solid organ transplant rejection, an autoimmune disease or a hyperproliferative disease. 
       
     
     
         32 . The method according to  claim 31  wherein X incorporates a radioisotope selected from the group consisting of  90 Y,  111 In,  177 Lu,  225 Ac,  213 Bi,  67 Ga,  68 Ga,  64 Cu,  67 Cu,  71 As,  72 As,  76 As,  77 As,  65 Zn,  76 Br,  48 V,  49 V,  203 Pb,  209 Pb,  212 Pb,  166 Ho,  153 Pm,  201 Tl,  188 Re,  186 Re,  186 Re,  99m Tc or a mixture thereof. 
     
     
         33 . The method according to  claim 31  wherein Y is a —(CH 2 ) n Z— group where n is 4, Z is a NR group and R is H, and which group links the nitrogen of said NR group to a 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) group and wherein said DOTA group incorporates or complexes with a radioisotope selected from the group consisting of  90 Y,  111 In,  177 Lu,  67 Ga,  68 Ga, and  213 Bi, or a pharmaceutically acceptable salt thereof. 
     
     
         34 . The method according to  claim 33  wherein said radioisotope is  90 Y,  213 Bi,  177 Lu or  111 In. 
     
     
         35 . The method according to  claim 33  wherein said radioisotope is  213 Bi,  177 Lu or  111 In. 
     
     
         36 . The method according to  claim 33  wherein said radioisotope is  213 Bi,  90 Y, or  177 Lu. 
     
     
         37 . The method according to  claim 33  wherein said radioisotope is  213 Bi. 
     
     
         38 . The method according to  claim 33  wherein said compound is 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt thereof 
       
     
     
         39 . The method according to  claim 31  wherein said disease state or condition is ischemia-reperfusion injury, reperfusion injury of tissue due to cardiopulmonary bypass, myocardial infarction, acute glomerulonephritis or vasculitis. 
     
     
         40 . The method according to  claim 31  wherein said disease state or condition is reactive arthritis, dermatosis, stroke, thermal injury, hemodialysis, ulcerative colitis, necrotizing enterocolitis, solid organ transplant rejection, an autoimmune disease or a hyperproliferative disease. 
     
     
         41 . The method according to  claim 31  wherein said disease state or condition is ischemia-reperfusion injury, reperfusion injury of tissue due to cardiopulmonary bypass, myocardial infarction, stroke, hemodialysis, acute glomerulonephritis or solid organ transplant rejection. 
     
     
         42 . A method of treating an ICAM-1/LFA-1 mediated disease state or condition in a patient in need comprising administering to said patient an effective amount of at least one compound according to the following chemical structure: 
       
         
           
           
               
               
           
         
         Where Y is a chemical linker which links the nitrogen to a chelate group or tricarbonyl complex X, wherein X incorporates or complexes with a radioisotope, or a pharmaceutically acceptable salt thereof, and said disease state or condition is an inflammatory disease, ischemia-reperfusion injury, reperfusion injury of tissue due to cardiopulmonary bypass, myocardial infarction, acute glomerulonephritis, vasculitis, reactive arthritis, dermatosis, stroke, thermal injury, hemodialysis, ulcerative colitis, necrotizing enterocolitis, solid organ transplant rejection, an autoimmune disease or a hyperproliferative disease. 
       
     
     
         43 . The method according to  claim 42  wherein X incorporates a radioisotope selected from the group consisting of  90 Y,  111 In,  177 Lu,  225 Ac,  213 Bi,  67 Ga,  68 Ga,  64 Cu,  67 Cu,  71 As,  72 As,  76 As,  77 As,  65 Zn,  76 Br,  48 V,  49 V,  203 Pb,  209 Pb,  212 Pb,  166 Ho,  153 Pm,  201 Tl,  188 Re,  186 Re,  186 Re,  99m Tc or a mixture thereof. 
     
     
         44 . The method according to  claim 42  wherein Y is a —(CH 2 ) n Z— group where n is 4, Z is a NR group and R is H, and which group links the nitrogen of said NR group to a 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) group and wherein said DOTA group incorporates or complexes with a radioisotope selected from the group consisting of  90 Y,  111 In,  177 Lu,  67 Ga,  68 Ga, and  213 Bi, or a pharmaceutically acceptable salt thereof. 
     
     
         45 . The method according to  claim 44  wherein said radioisotope is  90 Y,  213 Bi,  177 Lu or  111 In. 
     
     
         46 . The method according to  claim 44  wherein said radioisotope is  213 Bi,  177 Lu or  111 In. 
     
     
         47 . The method according to  claim 44  wherein said radioisotope is  213 Bi,  90 Y, or  177 Lu. 
     
     
         48 . The method according to  claim 44  wherein said radioisotope is  213 Bi or  111 In. 
     
     
         49 . The method according to  claim 44  wherein said radioisotope is  213 Bi or  90 Y. 
     
     
         50 . The method according to  claim 44  wherein said compound is 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt thereof. 
       
     
     
         51 . The method according to  claim 44  wherein said disease state or condition is ischemia-reperfusion injury, reperfusion injury of tissue due to cardiopulmonary bypass, myocardial infarction, acute glomerulonephritis or vasculitis. 
     
     
         52 . The method according to  claim 44  wherein said disease state or condition is reactive arthritis, dermatosis, stroke, thermal injury, hemodialysis, ulcerative colitis, necrotizing enterocolitis, solid organ transplant rejection, an autoimmune disease or a hyperproliferative disease. 
     
     
         53 . The method according to  claim 44  wherein said disease state or condition is ischemia-reperfusion injury, reperfusion injury of tissue due to cardiopulmonary bypass, myocardial infarction, stroke, hemodialysis, acute glomerulonephritis or solid organ transplant rejection. 
     
     
         54 . The method according to  claim 45  wherein said disease state or condition is ischemia-reperfusion injury, reperfusion injury of tissue due to cardiopulmonary bypass, myocardial infarction, acute glomerulonephritis or vasculitis. 
     
     
         55 . The method according to  claim 45  wherein said disease state or condition is reactive arthritis, dermatosis, stroke, thermal injury, hemodialysis, ulcerative colitis, necrotizing enterocolitis, solid organ transplant rejection, an autoimmune disease or a hyperproliferative disease. 
     
     
         56 . The method according to  claim 45  wherein said disease state or condition is ischemia-reperfusion injury, reperfusion injury of tissue due to cardiopulmonary bypass, myocardial infarction, stroke, hemodialysis, acute glomerulonephritis or solid organ transplant rejection.